Make sure to stay updated. HAEi will keep you informed when you sign up for our newsletter.
Sign up for HAEi Newsletter and register at the same time.
Tomtebodavägen 23A, Solna
SE-112 76 Stockholm
Swedish Orphan Biovitrum (Sobi) is a leading European specialty pharmaceutical company focused on providing and developing specialty pharmaceuticals for patients with rare diseases and significant medical needs. The portfolio comprises about 60 marketed products, as well as projects in late clinical phase. Key therapeutic areas are hematological diseases, autoimmune diseases, hereditary metabolic disorders and therapeutic oncology. Our vision is to be an exciting and leading international rare disease pharmaceutical company.
The Dutch biotechnology company, Pharming NV has developed the recombinant C1 inhibitor product (Ruconest), which is approved for the treatment of acute HAE, attacks by EMA. Ruconest is marketed in Europe and some other countries through their partner Swedish Orphan Biovitrum (Sobi). The product is derived from the milk of female rabbits that have been genetically altered to produce the human C1 inhibitor protein. Clinical trials have shown that Ruconest is a safe and effective treatment for acute HAE attacks.